Global and domestic drugmakers criticize latest state initiatives in Russia

Top Russian pharmaceutical manufacturers and global drugmakers, operating in the local market have called on the government to provide additional guarantees for the safety of their business in the country and to create conditions for their comfortable development in the local market.

Alexander Kuzin, chief executive of Novamedika, a leading Russian drugmaker, says that, in recent years, the growth of the Russian pharmaceutical market has slowed down significantly, mainly due to some of the latest state initiatives implemented in the market, including those in the field of pricing.

Mr Kuzin said the biggest protests from producers were related to the decision of the state to approve re-registration of prices for certain drugs from the list of vital medicines, which made their further supplies to the Russian market unprofitable for producers.